DRUG UTILIZATION REVIEW BOARD MEETING May 12, 2009 205 JEFFERSON STREET JEFFERSON CITY, MO 65101

Board Members Present by Phone:

John Newcomer, MD, Chairman Jennifer Passanise, FNP Charlene Heyde, RPh Sandra Bollinger, PharmD Sharad Parikh, M.D. David Campbell, M.D Joseph Yasso, DO

Board Members Absent:

Peggy Wanner-Barjenbruch, MD Joy Gronstedt, DO Randy Becker, PharmD Susan Abdel-Rahman, PharmD Stacy Mangum, PharmD

MO HealthNet Division Staff Present:

George L. Oestreich, PharmD, Deputy Division Director Rhonda Driver, RPh, Director Pharmacy Program Jay Bryant-Wimp, RPh, Clinical Pharmacist Allison Lauf, RN Jayne Zemmer, Program Manager Beth McQuaide, Administrative Assistant Mary Heet, RN

Others Attending:

- M. Patty Laster, Genentech Inc Eric Blake, Schering Plough C. Wycinowski, Pfizer Carol Curtis, Astrra Zeneca M Kloos, Pfizer
- C. Wycinowski, Pfizer Lon Lowry, Novartis Gamal Collier, Novartis R. Kilo, Pfizer

Welcome, Introductions and	Chairman, John Newcomer, M.D. called the conference call to order at 3:00 p.m. A quorum was established by roll call			
Opening Remarks	(See roll call votes). Dr. Newcomer summarized why the conference call had been called and noted the two items on			
	the agenda for the call were to ratify the recommendations made by the Committee of the Whole at the April 15, 2009			
	meeting and to discuss in more detail the PDL recommendation for the Statin drug class.			
Minutes Approval	Draft minutes of the April 15, 2009 meeting were e-mailed to all members prior to the conference call. These minutes			
	were reviewed and approved as submitted. By approval of the minutes the Drug Utilization Review (DUR) Board			
	ratified all recommendations made by the Committee of the Whole.			
Statins	• Discussion-Dr. Newcomer reminded members who attended the April 15, 2009 meeting and updated those who			
	were not in attendance on the discussion surrounding this class and the specifics of the Preferred Drug List (PDL)			
	recommendation under discussion, in particular the movement of two high potency agents to non-preferred status. This			
	discussion included seeking seamless approval, for secondary prevention needs, using data readily available and			
	captured electronically. Discussion ensued regarding what these criteria should be. Rhonda Driver, RPh, Director			
	Pharmacy Program stated that other clinical edits have similar criteria attached and it would not be difficult to build the			
	clinical arm into the Statin PDL edit. She also reminded the group that when a call to the help desk is required it is a			
	real time process. Members also discussed the possibility of allowing transparent, first line approval for high dose non			
	preferred agents, however determined, after discussion of utilization numbers, that this was not necessary.			
	• Decision-Following the discussion the motion to approve the Statin PDL recommendation with the modification to			
	allow transparent access to non preferred agents for those participants that meet defined or inferred diagnostic criteria			
	was made, seconded and passed. (See roll call votes)			
Adjourn	The call adjourned at approximately 3:40 p.m. MO HealthNet staff responded to several questions from audience			
	members including a short budget update and clarification of trial and failure language in the Inhaled Corticosteroid edit.			

Roll Call Votes - May 12, 2009

Member	Attendance	April 15, 2009 Minutes	Statins
Susan Abdel-Rahman	Absent	Absent	Absent
Randy Beckner	Absent	Absent	Absent
Sandra Bollinger	Yeah	Yeah	Second
Jennifer Passanise	Yeah	Motion	Yeah
David Campbell	Yeah	Yeah	Yeah
Joy S. Gronstedt	Absent	Absent	Absent
Stacy Mangum	Absent	Absent	Absent
John Newcomer	Yeah	Yeah	Yeah
Sharad Parikh	Yeah	Second	Yeah
Charlene Heyde	Yeah	Yeah	Yeah
Peggy Wanner- Barjenbruch	Absent	Absent	Absent
Joseph M. Yasso	Yeah	Yeah	Motion